NCT03174886View on ClinicalTrials.gov

A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia

PHASE1UnknownINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Primary Progressive Nonfluent Aphasia
Interventions
DRUG

AADvac1 40 µg

Active immunotherapy against neurofibrillary pathology.

DRUG

AADvac1 160 µg

Active immunotherapy against neurofibrillary pathology.

Trial Locations (3)

37075

Universitätsmedizin Göttingen, Klinik für Psychiatrie und Psychotherapie, Göttingen

81675

Klinikum Rechts der Isar der TU München, Klinik und Poliklinik für Psychiatrie und Psychotherapie, München

89081

Universitätsklinikum Ulm, Ulm

Sponsors
All Listed Sponsors
lead

Axon Neuroscience SE

INDUSTRY